In today’s recent session, 0.82 million shares of the Iovance Biotherapeutics Inc (NASDAQ:IOVA) have been traded, and its beta is 1.01. Most recently the company’s share price was $3.57, and it changed around -$0.06 or -1.71% from the last close, which brings the market valuation of the company to $1.17B. IOVA at last check was trading at a discount to its 52-week high of $15.50, offering almost -334.17% off that amount. The share price’s 52-week low was $3.42, which indicates that the recent value has risen by an impressive 4.2% since then. We note from Iovance Biotherapeutics Inc’s average daily trading volume that its 10-day average is 8.05 million shares, with the 3-month average coming to 9.58 million.
Iovance Biotherapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.40. If we narrow it down even further, the data shows that 0 out of 14 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 2 recommended IOVA as a Hold, whereas 8 deemed it a Buy, and 0 rated it as Underweight. Iovance Biotherapeutics Inc is expected to report earnings per share of -0.24 for the current quarter.
Iovance Biotherapeutics Inc (NASDAQ:IOVA) trade information
Instantly IOVA has been showing red trend so far today with a performance of -1.71% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 3.71 on recent trading dayincreased the stock’s daily price by 3.77%. The company’s shares are currently down -51.79% year-to-date, but still down -0.06% over the last five days. On the other hand, Iovance Biotherapeutics Inc (NASDAQ:IOVA) is -35.72% down in the 30-day period. We can see from the shorts that 59.59 million shares have been sold at a short interest cover period of 6.16 day(s).
The consensus price target as assigned by Wall Street analysts is $11.5, which translates to bulls needing to increase their stock price by 68.96% from its current value. Analyst projections state that IOVA is forecast to be at a low of $6 and a high of $17.
Iovance Biotherapeutics Inc (IOVA) estimates and forecasts
The year-over-year growth rate is expected to be 173.66%, up from the previous year.
Consensus estimates provided by 12 financial analysts predict the company will bring in an average of 83.36M in revenue for the current quarter. 12 analysts expect Iovance Biotherapeutics Inc to make 102.38M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 715k and 31.11M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 11,558.67%. Forecasts for the next quarter put sales growth at 229.13%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 4.17%.
Iovance Biotherapeutics Inc (NASDAQ:IOVA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.63% of Iovance Biotherapeutics Inc shares, and 84.02% of them are in the hands of institutional investors. The stock currently has a share float of 84.55%. Iovance Biotherapeutics Inc stock is held by 404.0 institutions, with VANGUARD GROUP INC being the largest institutional investor. By 2024-06-30, it held 9.7478% of the shares, which is about 25.95 million shares worth $208.12 million.
PERCEPTIVE ADVISORS LLC, with 9.1052% or 25.93 million shares worth $207.98 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Dec 31, 2024. The former held 8.61 shares worth $30.69 million, making up 2.63% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 7.38 shares worth around $26.32 million, which represents about 2.25% of the total shares outstanding.
